Camlin Fine Sciences Limited — PPTs, 23-05-2025: Investor Presentation

1. Financial Highlights:

Camlin Fine Sciences reported a 15% rise in consolidated revenue to ₹1666.5 Cr in FY25, with adjusted EBITDA up 13% to ₹208.1 Cr and a 12.5% EBITDA margin from its core business. The blends segment grew 18% to ₹878.4 Cr, driven by North America and domestic markets, while Aroma Ingredients revenue reached ₹175.8 Cr. Net debt reduced to ₹491.8 Cr, improving net debt-to-equity ratio to 0.55x from 0.65x. Q4FY25 revenue increased 16.1% YoY to ₹437.5 Cr, with a 13.6% EBITDA margin. PAT from continuing operations was ₹22.7 Cr, reflecting operational strength despite losses from legacy discontinued operations.

2. Strategic Initiatives & Growth Drivers:

The company is focusing on expanding high-margin blends and specialty ingredients for food, pet food, and pharma industries. Capex includes process enhancements for vanillin and HQ derivatives, with new dye, pigment, and agrochemical products slated for FY26. Vertical integration efforts aim to boost captive raw material use and expand blend and aroma product lines, maximizing capacity and supporting ‘Make in India’ growth.

3. Business Developments:

Camlin’s Mexico subsidiary acquired Vitafor Invest NV (Belgium), strengthening its footprint in European and African animal feed and pet food markets. This enhances cross-selling opportunities. R&D has scaled new antioxidant formulations commercially, including natural vanillin variants and emulsifier-based food ingredients.

4. Market Position & Competitive Advantage:

A global leader in antioxidants and specialty ingredients, Camlin benefits from strong vertical integration and a diverse portfolio—spanning antioxidants, blends, performance chemicals, and aromas. Its broad manufacturing base and wide customer reach drive growth, especially in North America and India, via customized high-value solutions.

5. Investor Implications:

Robust revenue and margin growth, deleveraging, and strategic acquisitions point to positive growth potential. Innovation and market expansion strengthen the outlook. Execution risks include acquisition integration and successful scaling of new specialty chemical launches in competitive markets.